Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis
Metrics: PDF 1600 views | HTML 2005 views | ?
Ran Ren1,*, Pengpeng Yin1,*, Yan Zhang1,*, Jianyun Zhou1, Yixing Zhou1, Rufu Xu1, Hai Lin2, Chunji Huang2
1Division of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
2Department of Scientific Research, Third Military Medical University, Chongqing, 400038, China
*These authors have contributed equally to this work
Hai Lin, email: [email protected]
Chunji Huang, email: [email protected]
Keywords: Fibulin-3, malignant pleural mesothelioma, diagnostic value, meta-analysis, systematic review
Received: September 08, 2016 Accepted: October 01, 2016 Published: October 17, 2016
Background: Several studies have investigated the diagnostic value of fibulin-3 for malignant pleural mesothelioma (MPM), but the results were various. Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic value of fibulin-3 for MPM.
Results: Eight studies were included in this work. The overall sensitivity of blood fibulin-3 were 0.87 (95% CI, 0.58 – 0.97) and 0.89 (95% CI, 0.77 – 0.95), respectively. The overall sensitivity and specificity of PF fibulin-3 for MPM were 0.73 (95% CI, 0.54 – 0.86) and 0.80 (95% CI, 0.60 – 0.91), respectively. The area under curve of blood and pleural effusion (PF) Fibulin-3 were 0.94 (95% CI, 0.91 – 0.96) 0.83 (95% CI, 0.79 – 0.86), respectively.
Methods: PubMed and EMBASE databases were searched up to July 29, 2016 to verify studies investigating the diagnostic value of fibulin-3 for MPM. The quality of eligible studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2). The overall sensitivity and specificity were pooled using a bivariate model.
Conclusion: Fibuoin-3 is a useful diagnostic marker for MPM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.